Which Immunoglobulin Route Best Prevents Infections?
In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection rates than the intravenous and facilitated subcutaneous routes.
METHODOLOGY:
Researchers conducted a cross-sectional study to compare the incidence of viral infections among immunocompromised patients who had been receiving IRT via different administration routes for more than 5 years.
They included 58 patients (56.8% boys; median age, 17 years; median age at diagnosis, 11.5 years) with inborn errors of immunity.
The intravenous route was the most common route of immunoglobulin administration (n = 32), followed by the conventional subcutaneous (n = 16) and facilitated subcutaneous (n = 10) routes.
Patients underwent monitoring of immunoglobulin levels and had nasal swab collected monthly, with viral infections recorded when symptoms such as runny nose, cough, or fever were present.
Infections from different immunoglobulin administration routes were analyzed by polymerase chain reaction testing of nasal swabs and serum immunoglobulin levels using nephelometry.
TAKEAWAY:
The overall viral infection frequency was 3.79%, with rates of 4.2% for the intravenous route, 2.5% for the conventional subcutaneous route, and 4.4% for the facilitated subcutaneous route of immunoglobulin administration.
The conventional subcutaneous route associated with significantly lower infection rates than the other routes (P < .05).
Adenovirus (21.8%), influenza A virus (16.4%), and human rhinovirus/enterovirus (16.4%) were the most frequently detected viral agents.
At 3 months, patients with X-linked agammaglobulinemia (6.06%) and those with common variable immunodeficiency (3.65%) had the highest rates of viral infections.
IN PRACTICE:
'Shared decision-making between patients and healthcare professionals is critical in determining the most appropriate administration route and product to minimize the risk of infections and achieve optimal treatment outcomes,' the authors wrote.
SOURCE:
The study was led by Hulya Kose, Department of Pediatric Immunology and Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey. It was published online on May 30, 2025, in the European Journal of Pediatrics.
LIMITATIONS:
This research had limitations due to the small sample size within specific patient subgroups.
DISCLOSURES:
The study did not receive any specific funding. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Moon phase today: What the moon will look like on June 30, 2025
It's the last moon in June, and there are plenty of geological features to see, even without a telescope, all thanks to the ever-changing lunar cycle. The lunar cycle is a series of eight unique phases of the moon's visibility. The whole cycle takes about 29.5 days, according to NASA, and these different phases happen as the Sun lights up different parts of the moon whilst it orbits Earth. See what's happening with the moon tonight, June 30. As of Monday, June 30, the moon phase is Waxing Crescent. 29% of the moon will be lit up and visible to us on Earth (according to NASA's Daily Moon Observation). This also marks the fifth day of the current lunar cycle, and there's plenty to spot on the moon's surface, with or without binoculars. Similarly to last night, there are two geological wonders you can spot with just your naked eye. These are the Mare Crisium and the Mare Fecunditatis. The Mare Crisium is also known as the "Sea of Crises and takes up around 109,000 square miles. The Mare Fecunditatis ("Sea of Fertility") is an impact basin that was the first spot where an automated sample retrieval took place in 1970. If you have binoculars or a telescope, you'll also spot the Endymion Crater. NASA tells us this crater is 78 miles in diameter and is defined by its dark, flat floor caused by cooled lava. June's full moon was on June 11. The next full moon will be on July 10. Moon phases are caused by the 29.5-day cycle of the moon's orbit, which changes the angles between the Sun, Moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. This is how we get full moons, half moons, and moons that appear completely invisible. There are eight main moon phases, and they follow a repeating cycle: New Moon - The moon is between Earth and the sun, so the side we see is dark (in other words, it's invisible to the eye). Waxing Crescent - A small sliver of light appears on the right side (Northern Hemisphere). First Quarter - Half of the moon is lit on the right side. It looks like a half-moon. Waxing Gibbous - More than half is lit up, but it's not quite full yet. Full Moon - The whole face of the moon is illuminated and fully visible. Waning Gibbous - The moon starts losing light on the right side. Last Quarter (or Third Quarter) - Another half-moon, but now the left side is lit. Waning Crescent - A thin sliver of light remains on the left side before going dark again.
Yahoo
42 minutes ago
- Yahoo
Ozempic Alternative Ditches The Needle And One Major Side Effect
A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to a new study. Although its efficacy hasn't yet been tested in humans, the compound could bypass some of the harmful side-effects associated with similar drugs. Unlike the famous family of GLP-1 receptor agonist drugs, this new candidate targets the β2-adrenergic receptor (β2AR). Drugs that do this aren't new: salbutamol (sold as Ventolin among other brand names) is widely prescribed for use in short stints to treat asthma and chronic obstructive pulmonary disease. Clenbuterol is also prescribed for asthma in some countries, though it's better known as a performance-enhancing drug, banned by the World Anti-Doping Agency for its anabolic effects. For more than a decade, scientists have been trying to find a way to harness the benefits of β2AR agonists, without setting off their harmful effects. They can stimulate skeletal muscle glucose uptake and burn fat, mimicking the effects of exercise – but they have been considered too risky for treating diabetes or obesity, because of their tendency to wreak havoc on the heart. Related: The body's β2-adrenergic receptors are coupled with G proteins, and when activated for long periods (by β2AR drugs, for instance), the G proteins set off a chain reaction which leads to cardiovascular problems. "That would lead to heart rate increases, systolic blood pressure increases, and, eventually, that over-sustained exposure would lead to increases in heart weight and cardiac hypertrophy," molecular biologist Shane Wright, from Karolinska Institute in Sweden, told Mar de Miguel of Bioworld. But a campaign led by scientists from the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB has revealed a series of β2AR agonist molecules that can side-step the slippery slope triggered by the G proteins. By activating only specific pathways, one of these – dubbed 'compound 15' – seems less likely to cause those concerning side effects, though we won't know for sure until further clinical trials are carried out. Unlike GLP-1 receptor agonists like Ozempic, compound 15 doesn't suppress appetite or lead to muscle loss, which means it may be safer in that regard too. It's also much more user-friendly, as a drug that can be swallowed rather than injected. "The goal was to try to target this other action that this receptor has expressed in the skeletal muscle, not in the heart, where it is mediating glucose uptake as a very beneficial outlet for lowering blood glucose levels," Wright said. So far, the newly-designed drug has been tested in lab-grown cells, male mice, rats, beagles, and phase 1 clinical trials (which only test for safety, not efficacy) in healthy and type 2 diabetic men. "Lead candidates of the chemical series increased glucose tolerance in preclinical models of diabetes and obesity with little or no increase in contractile force, cardiac lesions, and cardiac hypertrophy," the authors report. They also reversed muscle atrophy induced by GLP-1 drugs. "Clinical evaluation demonstrated that our lead candidate was orally bioavailable and safe in both healthy volunteers and type 2 diabetics, underlining its therapeutic potential." Many more tests – and a catchier name – will be needed before compound 15 or its relatives are made available as an alternative to GLP-1 drugs. Phase 2 clinical trials are underway to see if the enhanced muscle growth, balanced glucose levels, and insulin sensitivity seen in animal tests hold up in human bodies. "A well-tolerated GRK2-biased agonist offers significant therapeutic potential beyond type 2 diabetes and obesity… like muscular dystrophy and sarcopenia," the authors add. The research was published in Cell. A Simple Change To Your Evening Routine Could Help You Exercise More 'Sky-High' Levels of Alzheimer's Protein Found in Newborns Alzheimer's Might Not Actually Be a Brain Disease, Says Expert
Yahoo
42 minutes ago
- Yahoo
There's a Critical Thing We Can All Do to Hold Alzheimer's Symptoms at Bay
Deep sleep could forestall the declines in brain health that can eventually lead to Alzheimer's disease, the most common form of dementia. In their study of 62 older, cognitively healthy adults, researchers from the University of California (UC) Berkeley, Stanford University, and UC Irvine in the US found individuals with brain changes associated with Alzheimer's performed better on memory function tests as they got more deep sleep. This was irrespective of education and physical activity, two factors along with social connection known to contribute to cognitive resilience in older age. Those with similar Alzheimer's-linked changes who failed to get as much deep sleep didn't fare quite as well on the same tests. By comparison, sleep made little difference to those individuals with few deposits. Taken together, the results, which were published in May 2023, imply having a generous amount of solid shut-eye could help support the decline in memory that sets in as dementia begins to take hold. Watch the following video for a summary of the study: "Think of deep sleep almost like a life raft that keeps memory afloat, rather than memory getting dragged down by the weight of Alzheimer's disease pathology," said University of California (UC) Berkeley neuroscientist Matthew Walker. "This is especially exciting because we can do something about it. There are ways we can improve sleep, even in older adults." The study echoes previous research which has found a build-up of amyloid-beta proteins in the brains of people with disrupted sleep. But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and effect. Likewise, clumpy amyloid-beta proteins might only be a sign of Alzheimer's disease, not its root cause. Related: Even so, levels of amyloid-beta proteins are commonly used as a marker of Alzheimer's disease, as research suggests they – and another protein called tau – can start clogging up brain cells decades before symptoms of the disease arise. Past research from Walker's group found significant levels of amyloid-beta aggregating in the brains of older adults can disrupt deep sleep – also known as non-rapid eye movement slow wave sleep – and impair memory function. But some folk appear to stave off the decline that comes with Alzheimer's disease, even when levels of amyloid-beta proteins are relatively high. To find out why, Walker and colleagues monitored participants' brain waves as they slept, and then asked them to complete a memory test the next day. Among those whose brain scans revealed similarly high levels of beta-amyloid deposits, getting a good night's sleep seemed to make a critical difference in cognitive function. This effect was only seen when the researchers looked specifically at non-rapid eye movement slow wave sleep, and not at other sleep wave frequencies or sleep stages. Longer-term studies in older adults are needed to test whether increasing deep sleep over a number of years can actually help preserve a person's cognitive function in that time, even as levels of amyloid-beta increase. This research adds to scores of studies suggesting that sleep could be a modifiable risk factor for Alzheimer's disease, one that could potentially forestall molecular changes by giving the brain time to clean up waste products that accumulate during the day. It also points to sleep quality being important. "With a certain level of brain pathology, you're not destined for cognitive symptoms or memory issues," UC Berkeley neuroscientist and lead author Zsófia Zavecz said of the study findings in 2023. Although people may display molecular changes indicating a progression toward Alzheimer's disease, Zavecz says their findings suggest lifestyle factors can help buffer against those effects. "One of those factors is sleep and, specifically, deep sleep," she said. The study, though small, also hints at why getting good sleep naturally might be a better option than taking sleeping pills to get some shut-eye. Other research shows users of sleeping pills appear to have lower levels of amyloid proteins in their cerebrospinal fluid, which washes the brain clean at night. But these medications come with side effects; they may also lull people into shallow bouts of sleep rather than deep sleep phases. Instead, to set yourself up for a good night's sleep, Zavecz suggests cutting out coffee late in the day, doing some exercise, avoiding screen time, and taking a hot shower before bed. While you snooze, rest assured scientists are working hard to figure out the knotty problems of Alzheimer's disease, which affects millions of people worldwide. The study has been published in BMC Medicine. A version of this article was first published in May 2023. Ozempic Alternative Ditches The Needle And One Major Side Effect A Simple Change To Your Evening Routine Could Help You Exercise More 'Sky-High' Levels of Alzheimer's Protein Found in Newborns
